Petasin
Petasin is an orally active, potent inhibitor of mitochondrial electron transport chain complex I (ETCC1) with an IC50 of 3.55 μM. Petasin functionally activates AMPK by inhibiting mitochondrial respiration and increasing the intracellular AMP/ATP ratio. Petasin inhibits leukotriene production and eosinophil effector responses, as well as tumor cell proliferation, migration, invasion, and in vivo tumor growth and metastasis. Petasin is also a natural sesquiterpene ester that can be found in plants of the Petasites genus, such as Petasites japonicus and Petasites hybridus. Petasin can be used in studies related to cancer metabolism, glucose and lipid metabolism, and inflammation.
For research use only. We do not sell to patients.
- CAS No.: 26577-85-5
- Formula: C20H28O3
- Molecular Weight:316.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All AMPK Isoforms
More
Biological Activity
Description
IC50 & Target
[5]|
ETCC1 3.55 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SW-620 | IC50 |
30.07 μM
|
Cytotoxicity against human colon carcinoma SW-620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Cytotoxicity against human colon carcinoma SW-620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
30896562 |
| Caco-2 | IC50 |
209.67 μM
|
Cytotoxicity against human colon carcinoma Caco-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Cytotoxicity against human colon carcinoma Caco-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
30896562 |
| LoVo | IC50 |
228.59 μM
|
Cytotoxicity against human colon carcinoma LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Cytotoxicity against human colon carcinoma LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
30896562 |
| HT-29 | IC50 |
78.08 μM
|
Cytotoxicity against human colon carcinoma HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Cytotoxicity against human colon carcinoma HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
30896562 |
In Vitro
Petasin (for 6 days) potently inhibits adipocyte differentiation of 3T3-F442A cells, with an IC50 value of 0.95 μM[1].
Petasin (6 days) dose-dependently inhibits the expression of mature adipocyte markers (PPARγ, C/EBPα, aP2) and lipid synthesis factors (ACC1, FAS, SCD1) in differentiating 3T3-F442A cells[1].
Petasin (2 μM; 2-6 days) primarily inhibits the late stage of adipogenic differentiation in 3T3-F442A cells[1].
Petasin (1-25 μM; 24-72 h) dose-dependently inhibits the proliferation of SW-620, Caco-2, LoVo, and HT-29 colon cancer cells; the IC50 values at 48 h are 30.07, 209.67, 228.59, and 78.08 μM, respectively[7].
Petasin (15-150 nM) inhibits the migration of B16F10 cells, and reduces cell invasion and adhesion prior to the occurrence of energy depletion; Petasin also decreases focal adhesion and downregulates related signaling molecules including p-FAK, ITGA5, and Rac-GTP[5].
Petasin (25 μM; 48 h) induces apoptosis in human colon cancer SW-620 cells, which is characterized by an increased proportion of apoptotic cells and typical nuclear morphological changes[7].
Petasin (25 μM; 24 h) significantly inhibits the migration of human colon cancer SW-620 cells[7].
Petasin (25 μM; 24 h) significantly inhibits the invasive ability of human colon cancer cell line SW-620[7].
Petasin (25 μM; 24 h) reduces the phosphorylation of Akt, mTOR and P70S6K, increases the levels of Caspase-3 and Caspase-9, and decreases the expression of Bcl-2, MMP-3 and MMP-9 in SW-620 cells[7].
Petasin activates AMPK in H4IIE, C2C12 and 3T3-L1 cells; AMPK activation is observed at concentrations ≥ 0.3 μM in H4IIE cells, while the effective concentrations are ≥ 5 μM and ≥ 10 μM in C2C12 and 3T3-L1 cells, respectively[4].
Petasin reduces intracellular ATP levels and increases AMP and ADP levels in cultured cells, leading to dose-dependent increases in the AMP/ATP and ADP/ATP ratios; it also dose-dependently inhibits mitochondrial respiration driven by complex I substrates, without affecting respiration driven by complex II substrates[4].
Petasin potently inhibits mitochondrial complex I in isolated bovine heart mitochondria, with an IC50 of 3.55 μM[5].
Petasin (8-40 μg/mL; 15 min pre-incubation, followed by GM-CSF priming and agonist stimulation) dose-dependently inhibits cysteinyl-LT production in human eosinophils stimulated with PAF or C5a after GM-CSF priming, with an IC50 < 24 μg/mL; the inhibition rate reaches 68%-82% at 40 μg/mL[2].
Petasin (24 μg/mL; 20 min pre-incubation) inhibits cPLA2 activity in A23187-stimulated human eosinophils and prevents the translocation of 5-LO to the nuclear membrane[2].
Petasin dose-dependently inhibits ECP release from eosinophils stimulated by PAF or C5a, with an IC50 < 8 μg/mL; at 40 μg/mL, it inhibits PAF- and C5a-induced ECP release by 89.1% and 80.7%, respectively[2].
Petasin (40 μg/mL) inhibits the synthesis of cysteinyl leukotrienes in GM-CSF-prestimulated human eosinophils, as well as the synthesis of LTB4 in GM-CSF-prestimulated human neutrophils, with an IC50 ≤24 μg/mL; the inhibition rate reaches 68-94% at a concentration of 40 μg/mL[3].
Petasin (16 μg/mL) completely blocks the PAF- and C5a-induced elevation of intracellular Ca2+ in human eosinophils[2].
Petasin (16 μg/mL) inhibits PAF- and C5a-mediated increases in intracellular calcium concentrations in human eosinophils and human neutrophils in a dose-dependent manner, and completely blocks calcium signals at 16 μg/mL[3].
Petasin (3 μM; 72 h) potently inhibits the growth of various tumor cells and induces cell cycle arrest; subsequent mitochondrial damage, ATP depletion, and necrotic cell death occur in B16F10 cells, while non-tumor cells are less affected[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:3T3-F442A preadipocytes
-
Concentration:0.25-2 μM; 2 μM (structure-activity relationship testing)
-
Incubation Time:6 days
-
Result:Potently inhibited lipid accumulation in differentiating cells in a dose-dependent manner, with an IC50 value of 0.95 μM.
Reduced relative lipid accumulation to approximately 40% of the control level at 2 μM.
Showed no inhibitory effect at 2 μM for analogs isopetasin and petasol.
-
Cell Line:3T3-F442A adipocytes
-
Concentration:0.5-2 μM; 2 μM (structure-activity relationship testing)
-
Incubation Time:6 days
-
Result:Suppressed the mRNA expression of mature adipocyte markers (PPARγ, C/EBPα, aP2) in a dose-dependent manner, with near-complete inhibition at 2 μM.
Suppressed the expression of lipid synthesis factors (ACC1, FAS, SCD1) in a dose-dependent manner, with significant reductions observed at concentrations as low as 0.5 μM.
Showed no effect on the expression of any of these genes at 2 μM for analogs isopetasin and petasol.
-
Cell Line:SW-620, Caco-2, LoVo, HT-29
-
Concentration:1 μM, 5 μM, 25 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Exerted dose-dependent cytotoxicity on all four cell lines.
Reduced SW-620 cell growth by 21.16% at 24 h, 38.52% at 48 h, and 47.15% at 72 h when used at 25 μM.
Achieved IC50 values of 30.07 μM for SW-620, 209.67 μM for Caco-2, 228.59 μM for LoVo, and 78.08 μM for HT-29 at 48 h.
-
Cell Line:SW-620
-
Concentration:25 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of apoptotic SW-620 cells from 6.01% to 31.03%.
Induced clear nuclear condensation and structural changes in treated cells.
-
Cell Line:SW-620
-
Concentration:25 μM
-
Incubation Time:24 h
-
Result:Reduced the number of invasive SW-620 cells from 268 to 61 per microscope field.
-
Cell Line:SW-620
-
Concentration:25 μM
-
Incubation Time:24 h
-
Result:Reduced Akt/mTOR/P70S6K phosphorylation and altered apoptosis- and invasion-associated proteins.
-
Cell Line:H4IIE rat hepatoma cells
-
Concentration:0.1, 0.3, 0.5, 1, 5, 10 μM
-
Incubation Time:1 h
-
Result:Induced a dose-dependent increase in phosphorylated AMPKα (Thr172) and phosphorylated ACC (Ser79) levels, with increases observed at concentrations of at least 0.3 μM.
-
Cell Line:C2C12 mouse myotubes
-
Concentration:1, 10, 25, 50, 100, 200 μM
-
Incubation Time:2 h
-
Result:Induced a dose-dependent increase in phosphorylated AMPKα (Thr172) and phosphorylated ACC (Ser79) levels, with increases observed at concentrations of at least 5 μM.
-
Cell Line:differentiated 3T3-L1 mouse adipocytes
-
Concentration:1, 5, 10, 25, 50, 100 μM
-
Incubation Time:2 h
-
Result:Induced a dose-dependent increase in phosphorylated AMPKα (Thr172) and phosphorylated ACC (Ser79) levels, with increases observed at concentrations of at least 10 μM.
In Vivo
Petasin (200 mg/kg; p.o.; single administration) activates AMPK and its downstream signaling pathways in the liver, white adipose tissue and skeletal muscle of healthy mice[4].
Petasin (100-200 mg/kg; p.o.; single administration) is administered to fasted C57BL/6J mice 1 h prior to glucose loading, which significantly reduces the blood glucose AUC after glucose loading and enhances glucose tolerance[4].
Petasin (50 mg/kg; i.p.; once daily; for 4 consecutive days) significantly inhibits tumor growth in a B16F10 melanoma mouse model[5].
Petasin (50 mg/kg; i.p.; once daily; for 14 consecutive days) significantly reduces pulmonary tumor colonies in the B16F10 lung colonization model[5].
Petasin (50 mg/kg; i.p.; daily; for 14 consecutive days) potently inhibits spontaneous pulmonary metastasis and lymph node metastasis of Jyg-MCB breast cancer in mice, without affecting primary tumor growth or causing obvious acute toxicity[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c athymic (nu+/nu+) (male, 4 weeks old, colon cancer model via SW-620 cell hypodermic injection)[7]
-
Dosage:10 mg/kg
-
Administration:intragastrically; twice a day; 28 days
-
Result:Reduced tumor volume to 289.22 mm3 at day 21.
Reduced tumor volume to 577.67 mm3 at day 28.
Induced apoptosis in 36.0% of tumor cells.
-
Animal Model:C57BL/6J (male, 10 weeks old)[4]
-
Dosage:200 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased phosphorylation of AMPKα in liver, white adipose tissue, and skeletal muscle.
Increased phosphorylation of ACC (Ser79) in liver and white adipose tissue.
Increased relative mRNA expression of PGC-1α in skeletal muscle.
-
Animal Model:C57BL/6J (male, 10 weeks old)[4]
-
Dosage:100 mg/kg; 200 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced blood glucose levels after glucose loading compared to vehicle controls.
Lowered AUC values compared to vehicle controls.
-
Animal Model:C57BL/6 (orthotopic syngeneic B16F10 melanoma model)[5]
-
Dosage:50 mg/kg
-
Administration:i.p.; once daily for 4 d
-
Result:Significantly inhibited tumor growth.
-
Animal Model:immunocompromised (subcutaneous xenograft A2058 melanoma and NB-1 neuroblastoma models)[5]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:Significantly reduced tumor volume in both A2058 melanoma and NB-1 neuroblastoma xenograft models.
Caused no severe weight loss or apparent toxicity over the 14-day period.
-
Animal Model:syngeneic (spontaneous metastatic Jyg-MCB mammary carcinoma model)[5]
-
Dosage:50 mg/kg
-
Administration:i.p.; 6 administrations over 16 d
-
Result:Significantly reduced the number of lung metastatic lesions and the weight of enlarged axillary lymph nodes.
Reduced p-FAKY397-positive lung metastatic colonies and lowered percentages of Ki-67 and p-histone H3S10-positive proliferating cells in lung metastatic tissues.
Caused no significant growth inhibition of primary tumors and no severe weight loss or apparent toxicity.
Chemical Information
-
CAS No. 26577-85-5
-
Molecular Weight 316.43
-
Formula C20H28O3
-
SMILES
C[C@@]12C(CC[C@H]([C@@H]2C)OC(/C(C)=C\C)=O)=CC([C@@H](C1)C(C)=C)=O
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)